Neurocrine Biosciences | NBIX - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 608K 2026-06
Acadia Pharmaceuticals USD 172.31M 174K 2026-09
Agios Pharmaceuticals USD 59.6M 264K 2026-06
ALKERMES USD 168.03M 489K 2026-09
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Amgen USD 541M 0 2026-09
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Cytokinetics USD 138.76M 14.33M 2026-06
Enanta Pharmaceuticals USD 212K 1000 2023-12
Exelixis USD 244.68M 4.21M 2026-09
Gilead Sciences USD 1.24B 1000K 2026-06
Halozyme Therapeutics USD 113.94M 106K 2026-09
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 101.3M 750K 2026-09
Pfizer USD 5.7B 0 2026-06
Prothena USD 51.74M 1.33M 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Repligen USD 56.69M 266K 2026-09
Rigel Pharmaceuticals USD 17K 158K 2024-06
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
Teva Pharmaceutical Industries USD 1.17B 2M 2026-09
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
Vertex Pharmaceuticals USD 253.5M 200K 2026-09